People · Operator
Named in public records as an officer, director or promoter · active 2017–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lacerta Therapeutics, Inc. | — | Biotechnology | Series B | $30.5M | $1.2B | 2017 |
James D. Rusche at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James D. Rusche on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nicholas D. Muzyczka | 1 | 1 |
| Joseph D. Reddy | 1 | 1 |
| Barry D. Byrne | 1 | 1 |
| Kenneth D. Warrington | 1 | 1 |
| Sergei D. Zolotukhin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.